New amino acid combination which acts as a new treatment against obesity and liver steatosis.

The FATHIS project has the objective to develop a new therapy to ameliorate the obesity and non-alcoholic fatty liver disease (NAFLD) impact, as well their associated comorbidities.

The World Health Organisation (WHO) defines obesity as an excess of fat accumulation in adipose tissues and in other metabolic organs, leading to serious health implications.

Obesity is a rising issue whose prevalence has defined as a global pandemic being responsible of millions of deaths annually. Also, obesity is related with several comorbidities such as NAFLD, with a global prevalence of more than 25%.

Thus, strategies to ameliorate obesity and NAFLD are critical to improve life expectancy and quality of life and to reduce the economic burden of both diseases. In this sense, the new product developed in FATHIS project aims to help reduce the visceral obesity and liver steatosis.

Eurecat participates in the FATHIS project through its Nutrition and Health Unit, which works in a nutraceutical intervention pilot study in obesity and NAFLD patients.

General details


FATHIS – Modulation of histidine metabolism for the regulation of visceral adiposity and NAFLD

Project reference


Programme and call for tender

This project has been co-financed by the European Union through the European Regional Development Fund (ERDF) and has the support of the Secretary for Universities and Research of the Department of Business and Knowledge of the Generalitat de Catalunya. The project is part of the Knowledge Industry call for the year 2021 (Modality B.Product) and has received a grant of €100,000